Abstract
Objective: To comprehensively characterize the DNA virome in semen samples collected for in vitro fertilization (IVF). Design: A descriptive clinical study. Setting: Single academic fertility center. Patient(s): Twenty-four male partners from couples undergoing IVF. Intervention(s): Couples were randomized to receive 1 g of azithromycin (standard of care) or no azithromycin at the time of baseline IVF assessment. Semen samples were collected at the time of the female partners’ egg retrieval, and 100 μL of the sample was used for the virome analysis. Main Outcome Measure(s): Detection of viruses by ViroCap enrichment of viral nucleic acid and sequencing. Association between the virome, semen parameters, and pregnancy outcomes. Result(s): We detected viruses in 58% of the participants. Viruses included polyomaviruses, papillomaviruses, herpesviruses, and anelloviruses. Viromes detected in semen had little overlap with the viromes detected in vaginal samples from their female partners collected at the time of embryo transfer, which were analyzed in a previous study. A lower viral diversity in semen samples was positively associated with pregnancy (Hodges-Lehmann estimate of difference, 1; 95% confidence interval, 2–0.00003). There was no association between viral diversity and sperm concentration, motility, or fertilization rates. Conclusion(s): This comprehensive characterization of the DNA virome in semen reveals an association between virome diversity and pregnancy in couples undergoing IVF. However, no association was found with specific semen parameters or fertilization rates, suggesting that viral exposure may negatively affect pregnancy after fertilization. Future studies should be undertaken to evaluate the associations between the semen virome with IVF outcomes in larger cohorts.
Original language | English (US) |
---|---|
Pages (from-to) | 2-9 |
Number of pages | 8 |
Journal | F and S Science |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2022 |
Funding
This project was supported by the Washington University Institute of Clinical and Translational Sciences which is, in part, supported by the NIH/National Center for Advancing Translational Sciences (NCATS) , CTSA grant UL1TR002345 , and by the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital . This project was supported by the Washington University Institute of Clinical and Translational Sciences which is, in part, supported by the NIH/National Center for Advancing Translational Sciences (NCATS), CTSA grant UL1TR002345, and by the Children's Discovery Institute of Washington University and St. Louis Children's Hospital. S.G. has nothing to disclose. A.M.E. reports grant from National Institute of Child Health and Human Development of the National Institutes of Health grant number T32HD055172 as a part of the Reproductive Epidemiology Training Program at Washington University in St. Louis for the submitted work. D.S. has nothing to disclose. J.K.R. has nothing to disclose. M.J.S. has nothing to disclose. J.S. has nothing to disclose. E.S.J. reports grant from NIH - RO1HD100318 outside the submitted work. K.M.W. has nothing to disclose. Patent for ViroCap, which is used in this study, US20170218465A1 compositions and methods for detecting viruses in a sample. S.G. has nothing to disclose. A.M.E. reports grant from National Institute of Child Health and Human Development of the National Institutes of Health grant number T32HD055172 as a part of the Reproductive Epidemiology Training Program at Washington University in St. Louis for the submitted work. D.S. has nothing to disclose. J.K.R. has nothing to disclose. M.J.S. has nothing to disclose. J.S. has nothing to disclose. E.S.J. reports grant from NIH - RO1HD100318 outside the submitted work. K.M.W. has nothing to disclose. Patent for ViroCap, which is used in this study, US20170218465A1 compositions and methods for detecting viruses in a sample.
Keywords
- IVF
- semen
- virome
ASJC Scopus subject areas
- Reproductive Medicine
- Embryology